Andrieu G, Belkina AC, Denis GV (2016) Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol 19:45–50

Article  PubMed  PubMed Central  Google Scholar 

Ayen A, Jimenez Martinez Y, Marchal JA, Boulaiz H (2018) Recent Progress in Gene Therapy for Ovarian Cancer. Int J Mol Sci 19(7):1930

Article  PubMed  PubMed Central  Google Scholar 

Bagratuni T, Mavrianou N, Gavalas NG et al (2020) JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. Eur J Cancer 126:125–135

Article  CAS  PubMed  Google Scholar 

Baratta MG, Schinzel AC, Zwang Y et al (2015) An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A 112:232–237

Article  CAS  PubMed  Google Scholar 

Bard-Chapeau EA, Gunaratne J, Kumar P et al (2013) EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation. Proc Natl Acad Sci U S A 110:E2885–E2894

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bard-Chapeau EA, Jeyakani J, Kok CH et al (2012) Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci U S A 109:2168–2173

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bleu M, Mermet-Meillon F, Apfel V et al (2021) PAX8 and MECOM are interaction partners driving ovarian cancer. Nat Commun 12:2442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

Article  PubMed  Google Scholar 

Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G (2001) Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem 276:44936–44943

Article  CAS  PubMed  Google Scholar 

Cuellar-Partida G, Lu Y, Dixon SC et al (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741–756

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng X, Cao Y, Liu Y et al (2013) Overexpression of Evi-1 oncoprotein represses TGF-beta signaling in colorectal cancer. Mol Carcinog 52:255–264

Article  CAS  PubMed  Google Scholar 

Di Micco R, Fontanals-Cirera B, Low V et al (2014) Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep 9:234–247

Article  PubMed  PubMed Central  Google Scholar 

Duan Y, Guan Y, Qin W, Zhai X, Yu B, Liu H (2018) Targeting Brd4 for cancer therapy: inhibitors and degraders. Medchemcomm 9:1779–1802

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fulco CP, Nasser J, Jones TR et al (2019) Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations. Nat Genet 51:1664–1669

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goyama S, Kurokawa M (2010) Evi-1 as a critical regulator of leukemic cells. Int J Hematol 91:753–757

Article  CAS  PubMed  Google Scholar 

Khazaei Z, Namayandeh SM, Beiranvand R, Naemi H, Bechashk SM, Goodarzi E (2021) Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018. J Prev Med Hyg 62:E174–E184

PubMed  PubMed Central  Google Scholar 

Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304

Article  PubMed  Google Scholar 

Liu K, Tirado CA (2019) MECOM: A Very Interesting Gene Involved also in Lymphoid Malignancies. J Assoc Genet Technol 45:109–114

PubMed  Google Scholar 

Loven J, Hoke HA, Lin CY et al (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153:320–334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurano MT, Humbert R, Rynes E et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337:1190–1195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizuguchi A, Yamashita S, Yokogami K, Morishita K, Takeshima H (2019) Ecotropic viral integration site 1 regulates EGFR transcription in glioblastoma cells. J Neurooncol 145:223–231

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nanjundan M, Nakayama Y, Cheng KW et al (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67:3074–3084

Article  CAS  PubMed  Google Scholar 

Ong CT, Corces VG (2011) Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet 12:283–293

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel JB, Appaiah HN, Burnett RM et al (2011) Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 30:1290–1301

Article  CAS  PubMed  Google Scholar 

Phelan CM, Kuchenbaecker KB, Tyrer JP et al (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet 49:680–691

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qiu H, Jackson AL, Kilgore JE et al (2015) JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. Oncotarget 6:6915–6930

Article  PubMed  PubMed Central  Google Scholar 

Roadmap Epigenomics C, Kundaje A, Meuleman W et al (2015) Integrative analysis of 111 reference human epigenomes. Nature 518:317–330

Article  Google Scholar 

Sayadi A, Jeyakani J, Seet SH et al (2016) Functional features of EVI1 and EVI1Delta324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity. Oncogene 35:2311–2321

Article  CAS  PubMed  Google Scholar 

Shimabe M, Goyama S, Watanabe-Okochi N et al (2009) Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene 28:4364–4374

Article  CAS  PubMed  Google Scholar 

Spicuglia S, Vanhille L (2012) Chromatin signatures of active enhancers. Nucleus 3:126–131

Article  PubMed  PubMed Central  Google Scholar 

Sun C, Yin J, Fang Y et al (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401–416 e408

Article  CAS